These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38468478)
1. Clinical and economic burden of systemic lupus erythematosus in Colombia. Elsisi GH; Quintana G; Gil D; Santos P; Fernandez D J Med Econ; 2024; 27(sup1):1-11. PubMed ID: 38468478 [TBL] [Abstract][Full Text] [Related]
2. The economic burden of systemic lupus erythematosus in Taiwan. Elsisi GH; Hsieh SC; Chen DY J Med Econ; 2024; 27(sup1):56-66. PubMed ID: 38468480 [TBL] [Abstract][Full Text] [Related]
3. Economic burden of systemic lupus erythematosus in Malaysia. Elsisi GH; Joe AY; Zain MM; Yusoof HM; Teh CL; Mohd AB; Khor XT; Isa LBM J Med Econ; 2024; 27(sup1):46-55. PubMed ID: 38468479 [TBL] [Abstract][Full Text] [Related]
4. The economic burden of systemic lupus erythematosus in United Arab Emirates. Alansari A; Hannawi S; Aldhaheri A; Zamani N; Elsisi GH; Aldalal S; Naeem WA; Farghaly M J Med Econ; 2024; 27(sup1):35-45. PubMed ID: 38468482 [TBL] [Abstract][Full Text] [Related]
5. The economic burden of systemic lupus erythematosus in Mexico. Elsisi GH; Andrade-Ortega L; Portela M; Ramírez GM J Med Econ; 2024; 27(sup1):12-22. PubMed ID: 38468477 [TBL] [Abstract][Full Text] [Related]
6. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745 [TBL] [Abstract][Full Text] [Related]
7. Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States. Wu SS; Perry A; Tkacz J; Bryant G J Manag Care Spec Pharm; 2023 Sep; 29(9):1010-1020. PubMed ID: 37610115 [No Abstract] [Full Text] [Related]
8. Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia. Gil-Rojas Y; Amaya-Granados D; Quiñones J; Robles A; Samacá-Samacá D; Hernández F Mult Scler Relat Disord; 2024 Feb; 82():105376. PubMed ID: 38141561 [TBL] [Abstract][Full Text] [Related]
9. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. Narayanan S; Wilson K; Ogelsby A; Juneau P; Durden E J Occup Environ Med; 2013 Nov; 55(11):1262-70. PubMed ID: 24202242 [TBL] [Abstract][Full Text] [Related]
10. The humanistic and economic burden of systemic lupus erythematosus : a systematic review. Meacock R; Dale N; Harrison MJ Pharmacoeconomics; 2013 Jan; 31(1):49-61. PubMed ID: 23329592 [TBL] [Abstract][Full Text] [Related]
11. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074 [TBL] [Abstract][Full Text] [Related]
12. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. Kariburyo F; Xie L; Sah J; Li N; Lofland JH J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081 [No Abstract] [Full Text] [Related]
13. The impact of flare on disease costs of patients with systemic lupus erythematosus. Zhu TY; Tam LS; Lee VW; Lee KK; Li EK Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597 [TBL] [Abstract][Full Text] [Related]
14. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States. Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505 [TBL] [Abstract][Full Text] [Related]
15. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015. Jiang M; Near AM; Desta B; Wang X; Hammond ER Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733 [TBL] [Abstract][Full Text] [Related]
16. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. Khamashta MA; Bruce IN; Gordon C; Isenberg DA; Ateka-Barrutia O; Gayed M; Donatti C; Guillermin AL; Foo J; Perna A Lupus; 2014 Mar; 23(3):273-83. PubMed ID: 24356612 [TBL] [Abstract][Full Text] [Related]
17. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Bell CF; Huang SP; Cyhaniuk A; Averell CM Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670 [TBL] [Abstract][Full Text] [Related]
18. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015. Hammond ER; Desta B; Near AM; Wang X; Jiang M Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34556546 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus. Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ Adv Ther; 2023 Jan; 40(1):194-210. PubMed ID: 36266383 [TBL] [Abstract][Full Text] [Related]
20. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus. Lokhandwala T; Coutinho AD; Bell CF Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]